Table 2.

Neuropathy assessments at baseline and 36 months in subjects who reverted to NGT, remained with IGT, or developed type 2 diabetes at 36 months

	Control (N = 17)		NGT (N = 5)		IGT (N = 15)		Type 2 diabetes (N = 10)
	Baseline	36 months	Baseline	36 months	Baseline	36 months	Baseline	36 months
HbA1c (mmol/mmol)	38.3 ± 0.7	37.7 ± 0.9	41.4 ± 2.3	40.5 ± 2.4	42.8 ± 1.2	42.3 ± 2.3	42.4 ± 1.0	50.3 ± 1.4∼
NSP (/10)	0.3 ± 0.1	0.4 ± 0.2	3.6 ± 1.4†	1.8 ± 1.3	4.0 ± 1.3†	4.2 ± 1.2	2.5 ± 0.9†	3.0 ± 1.3
NDS (/10)	1.1 ± 0.3	1.4 ± 0.2	3.8 ± 2.0*	4.8 ± 2.2	2.5 ± 0.6*	2.3 ± 0.5	3.5 ± 1.4*	1.6 ± 1.6
VPT (V)	8.4 ± 1.5	9.1 ± 1.8	19.3 ± 3.5*	24.2 ± 7.1	13.5 ± 3.4*	13.3 ± 2.6	16.9 ± 3.3*	17.3 ± 3.5
SNCV (m/s)	49.0 ± 1.1	46.0 ± 1.6	47.9 ± 2.6	44.2 ± 3.2	50.8 ± 1.4	46.3 ± 1.9	50.1 ± 2.3	47.1 ± 2.0
SNAP (μV)	15.3 ± 1.8	13.2 ± 2.7	8.8 ± 2.6	6.3 ± 2.0	12.5 ± 1.5	11.3 ± 1.7	11.0 ± 2.5	12.0 ± 3.4
PMNCV (m/s)	46.5 ± 1.0	45.0 ± 1.4	44.1 ± 2.4	44.5 ± 2.2	45.9 ± 1.2	45.7 ± 2.5	44.7 ± 1.2	44.1 ± 1.0
PMNA (mV)	5.2 ± 0.4	5.3 ± 0.3	3.2 ± 0.6	3.2 ± 0.6	3.8 ± 0.4	3.8 ± 0.4	4.6 ± 0.6	4.2 ± 0.6
CT (°C)	27.9 ± 1.1	27.6 ± 0.4	22.9 ± 1.0	20.3 ± 3.9	29.2 ± 1.6	26.5 ± 0.6	24.8 ± 2.5	25.0 ± 1.4
WT (°C)	39.5 ± 1.1	38.8 ± 0.6	42.8 ± 1.9	41.5 ± 2.5	38.8 ± 1.7	40.1 ± 1.2	39.6 ± 1.1	40.1 ± 1.0
IENFD (no./mm)	8.5 ± 0.6		6.5 ± 1.1	3.0 ± 0.4∼	6.7 ± 1.1	2.8 ± 0.3∼	6.5 ± 1.2	3.9 ± 0.9∼
MDL (μm)	63.0 ± 4.2		25.1 ± 3.7†	27.5 ± 4.2	27.9 ± 2.1†	29.3 ± 3.8	21.9 ± 2.1†	16.5 ± 0.3∼
CNFD (no./mm2)	30.7 ± 1.5	29.7 ± 1.4	25.4 ± 1.9	29.8 ± 1.5*	28.6 ± 1.5	27.9 ± 1.3	20.0 ± 2.2^	18.3 ± 1.7
CNBD (no./mm2)	37.0 ± 2.7	39.0 ± 3.2	29.3 ± 5.6	44.9 ± 6.2#	38.8 ± 3.7	38.7 ± 3.1	25.6 ± 5.2#	21.8 ± 3.9
CNFL (mm/mm2)	20.4 ± 3.14	19.2 ± 0.9	15.7 ± 1.3	17.2 ± 0.9*	16.8 ± 0.8	16.2 ± 0.6	13.7 ± 1.2#	11.8 ± 1.0+

Data are means ± SEM. All symbols represent statistically significant differences.

∼P = 0.02,

#P = 0.04,

*P = 0.05,

^P = 0.003,

+P = 0.0006,

†P < 0.0001, baseline vs. control or baseline vs. 36 months.